Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Doxorubicin + Docetaxel/Cisplatin in NSCLC
NCT00082472Phase 2Unknown
- Sponsor
- Zivena
- Start
- Jan 2004
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in non-small cell lung cancer (NSCLC), sponsored by Zivena. Primary endpoints: Maximal Tolerated Dose and Therapeutic Activity. Status: unknown.
02
Drugs
doxorubicin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00082472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082472.